NASDAQ:CAPS Capstone Therapeutics Q3 2026 Earnings Date & Estimates $2.07 -0.07 (-3.27%) Closing price 11/4/2026 04:00 PM EasternExtended Trading$2.24 +0.17 (+7.97%) As of 11/4/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Capstone Therapeutics is estimated to report Q3 2026 earnings on Friday, November 6, 2026, before market opens. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 6, 2026TimeBefore Market Opens Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Capstone Therapeutics in Q3 2026Capstone Therapeutics is expected to post earnings of $5.70 per share on revenue of $24.60 million. In the same quarter a year earlier Capstone Therapeutics reported -$10.50 per share on revenue of $13.65 million. Capstone Therapeutics last reported on May 20, 2026, posting -$6.30 per share and missing the -$5.70 consensus estimate.Consensus EstimatesConsensus EPS$5.70Expected Revenue$24.60 millionPrior-Year EPS-$10.50Prior-Year Revenue$13.65 millionExpected Revenue Growth+80.1%Recent Track RecordLast ReportedQ1 2026Last Quarter EPS-$6.30 (Missed by -$0.60)Last Quarter Revenue$12.64 millionPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ1 2026 Earnings ReportQ3 2025 Earnings ReportQ2 2025 Earnings Report Capstone Therapeutics Q3 2026 Earnings FAQ When does Capstone Therapeutics report Q3 2026 earnings? Capstone Therapeutics (NASDAQ:CAPS) is estimated to report Q3 2026 earnings on Friday, November 6, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Capstone Therapeutics' Q3 2026 earnings call? Capstone Therapeutics' Q3 2026 earnings conference call is scheduled for Wednesday, November 18, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Capstone Therapeutics? Analysts expect Capstone Therapeutics to post earnings of $5.70 per share for Q3 2026. How much revenue is Capstone Therapeutics expected to report? The consensus revenue estimate for Capstone Therapeutics is $24.60 million for Q3 2026. Capstone Therapeutics Earnings HeadlinesCapstone Therapeutics (CAPS) Set to Post Earnings on FridayOctober 30, 2026 | americanbankingnews.comCapstone Therapeutics (NASDAQ:CAPS) Stock Price Up 0.8% - Here's What HappenedOctober 27, 2026 | americanbankingnews.comThe $100 Stock Behind Elon's Next MoveA federal filing may reveal Elon Musk's next big move: a satellite network running AI in orbit, powered by the sun. One small, publicly traded supplier reportedly plays a key role in making that vision possible, with shares trading for less than $100. December 8th is being flagged as a date worth watching for this little-known company. | Paradigm Press (Ad)Capstone Publishes Investor FAQ: 75% of Convertible Note Principal Retired, Approximately $1.72 Million RemainingAugust 26, 2026 | businesswire.comCapstone Reports Q2 2026 Results: Revenue Up 67%, Gross Profit Up 92%, Stone Business Adjusted EBITDA Turns Positive as GuidedAugust 12, 2026 | businesswire.comCapstone Receives Additional 180-Day Nasdaq Compliance PeriodJuly 9, 2026 | businesswire.comSee More Capstone Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Capstone Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Capstone Therapeutics and other key companies, straight to your email. Email Address About Capstone TherapeuticsCapstone Therapeutics (NASDAQ:CAPS) Corporation was a biotechnology company focused on developing peptide-based therapeutics for tissue repair and regenerative medicine. Its research programs centered on synthetic peptides designed to influence healing and recovery in areas such as bone, soft tissue and cardiovascular injury. The company’s principal historical programs included Chrysalin (TP508), an experimental peptide derived from a portion of the human thrombin protein that was investigated for applications in bone and tissue healing, and AZX100, a peptide-based candidate studied for its potential to reduce fibrosis and postsurgical scarring. These candidates remained development-stage programs rather than widely marketed commercial products. Capstone Therapeutics was based in the United States and served the biotechnology and pharmaceutical markets through research, development and potential licensing or partnering activities. Publicly available information about its later operations, leadership and commercial status is limited, and the company is primarily described in historical sources as a development-stage therapeutics business.View Capstone Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains3 Dividend Increases Above 10%, But Which Offers the Most Income?High Voltage Returns: Talen Energy Powers the Data Center RushBloom Energy: The Off-Grid Answer to AI's Power DrainWhy ExxonMobil and Chevron Reminded Investors to Keep it SimpleEnergy Transfer's Earnings Miss May Be Hiding Its Strongest Advantage Upcoming Earnings Enbridge (11/6/2026)Brookfield Asset Management (11/6/2026)Humana (11/6/2026)Moderna (11/6/2026)Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
